Skip to main content
Figure 4 | Journal of Translational Medicine

Figure 4

From: NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols

Figure 4

Effect of NCX-4040 and/or cisplatin (cDDP) on the growth volume of human ovarian cancer xenograft tumor in mice. Groups of mice (4–6 per group) were inoculated with the A2780 cDDP human ovarian cancer cells in the upper portion of hind leg. Seven days after inoculation, two groups were injected daily (i.p.) with NCX-4040 (5 mg/kg), of which one group received a single i.p. injection of cisplatin on day 11 (8 mg/kg). The third group received single dose of cisplatin on day 11 (8 mg/kg). One group received aspirin (5 mg/kg, daily). Control group received vehicle. (A) Tumor growth curve for control, cisplatin, and combination of treatment (NCX-4040 and cisplatin). (B) Tumor growth volume data (mean ± SE, expressed as percent of control group) on the 19th day after injection of cancer cells. *p < 0.05 compared to control group. **p < 0.05 versus cDDP group. NCX-4040 and aspirin (ASA), a metabolic product of NCX-4040, showed no significant effect. The results show that pretreatment with NCX-4040 was effective in enhancing the efficacy of cisplatin in inhibiting the growth of cisplatin-resistant ovarian cancer xenografts in mice.

Back to article page